

Day One
Wednesday 25th April, 2018

08.00 Breakfast & Registration

08.30 Chairman's Opening Remarks

Jeroen van Bergen, Director of Research, Immunetune

Optimising the Identification and Prediction of Neoantigens

08.45 Immunopeptidomics: Accelerating the Development of Personalised Cancer Immunotherapy – How can we Improve Identification and Prioritisation of Neoantigens with MS Based Immunopeptidomics?

Michal Bassani-Sternberg, Immunopeptidomics Unit, Center of Experimental Therapeutics, Department of Oncology, UNIL/CHUV

09.15 Advances in the Field of In-silico Methods for the Identification of Neoepitopes

Morten Nielsen, Professor, Group leader Immunoinformatics and Machine-Learning, Department of Bio and Health Informatics,, The Technical University of Denmark

09.45 An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

Trevor Clancy, Co-Founder & CSO, Oncolmmunity

10.15 Speed Networking

Jennifer MacKay, Commercial Director, Hanson Wade

10.45 Morning Refreshments

11.15 Overcoming Neoantigen Prediction Challenges in Clinical Application

Martin Löwer, Head of Bioinformatics, TRON

11.45 Panel: Determining Best Practices for Neoantigen Prediction

Jim Johnston, Executive Director, Inflammation, Amgen

Martin Löwer, Head of Bioinformatics, TRON


Michal Bassani-Sternberg, Immunopeptidomics Unit, Center of Experimental Therapeutics, Department of Oncology, UNIL/CHUV

Nadine Defranoux, Program Manager, Parker Institute for Cancer Immunotherapy


12.15 From Sample to Neoantigens for Vaccines: Key Challenges and Solutions

Sean Michael Boyle, Director, Bioinformatics Applications, Personalis

12.45 Lunch & Networking



- 13.45 Optimising the Neoantigenic Landscape in Low Mutational Burden Tumours for Optimal T Cells Response**
Sebastiano Battaglia, Assistant Professor of Oncology, Centre of Immunotherapy, Roswell Park Cancer Centre
- 14.15 Identification and Characterization of Presented Tumour Neo-Epitopes from Metastatic Colon Cancer**
Eustache Paramithiotis, Vice-President, Discovery, Caprion Biosciences Inc
- 14.45 Sensitive Identification and Functional Profiling of Neoepitopespecific T Cells**
Alexandre Harari, Professor, CHUV
- 15.15 Afternoon Refreshments & Networking**
- 15.45 Immunogenicity of Neoantigen Cancer Vaccines**
Hyewon Phee, Senior Scientist & Project Manager, Inflammation, Amgen
- 16.15 Determinants of Immunogenicity of Neoantigens**
Suchit Jhunhunwala, Scientist, Bioinformatics & Computational Biology, Genentech
- 16.45 Chairman's Closing Remarks**
Jeroen van Bergen, Director of Research, Immunetune
- 17.00 Close of Day One**



Day Two
Thursday 26th April, 2018

08.00 Breakfast & Networking

09.00 Chairman's Opening Remarks
Mohamed Uduman, Scientist, Agenus

Advancing Cell & Vaccine-based Therapies

09.15 Reinvigorating Cancer Vaccines with Neoantigen Targeting Individualised mRNA-based Vaccines for the Treatment of Cancer
Matthias Miller, Senior Project Manager, BioNTech

09.45 Live-Attenuated Double Deleted Listeria Monocytogenes (pLADD) Immunotherapy Targeting MSS CRC
Andrea van Elsas, CSO, Aduro Europe

10.15 Personalised Onco-Immunotherapy: in vivo and ex vivo Vaccination Trials
Toni Weinschenk, Founder & CTO, Immatix Biologics

10.45 Morning Refreshments & Networking


11.15 Fast and Cost-Effective Oral Delivery Technology of Personalized T-Cell Vaccines Based on a Live Attenuated Bacteria Platform
Heinz Lubenau, COO, VAXIMM GmbH

11.45 Panel: Maximizing the Potential of Neoantigen-based Targeting for Cancer Vaccines
Pamela Carroll, SVP, Immuno-Oncology, Genocera Biosciences
Matthias Miller, Senior Project Manager, BioNTech
Andrea van Elsas, CSO, Aduro Europe
Toni Weinschenk, Founder & CTO, Immatix Biologics

Guaranteeing Immunogenicity

12.45 A New Source of Highly Immunogenic Neoepitopes for Cancer Vaccines
Stephen Johnston, Director, Centre for Innovations in Medicine, Biodesign Institute, Arizona State University

13.15 Lunch & Networking



Overcoming Manufacturing Challenges for Personalised Therapies

- 14.15 Redirecting Anti-Viral Immunity to Fight Cancer with Tumor Specific Neoantigens**
Kaïdre Bendjama, Personalized, Vaccination Project, Lead Transgene S.A.
- 14.45 Individualised Cancer Neoantigen Vaccines: How can we Make it a Viable Product?**
Agnete Fredriksen, CSO, Vaccibody
- 15.15 Afternoon Refreshments & Networking**
- 15.45 Manufacturing and Treatment of Patients with Individualized Neoantigen Therapies**
Mohamed Uduman, Scientist, Agenus
- 16.15 Panel: Advancing Manufacturing Practices for Personalized Cancer Vaccines**
Agnete Fredriksen, CSO, Vaccibody
Matthias Miller, Senior Project Manager, BioNTech
Heinz Lubenau, COO, VAXIMM GmbH
Kaïdre Bendjama, Personalized, Vaccination Project, Lead Transgene S.A.
- 17.15 Chairman's Closing Remarks**
Mohamed Uduman, Scientist, Agenus
- 17.30 Close of Summit**